Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: A multicenter feasibility study

Bone Marrow Transplantation

Volumn 45, Issue 7, 2010, Pages 1147-1153

  Musso, M ^a   Scalone, R ^a   Marcacci, G ^b   Lanza, F ^c   Di Renzo, N ^d   Cascavilla, N ^e   Di Bartolomeo, P ^f   Crescimanno, A ^a   Perrone, T ^g   Pinto, A ^b  

^a LA MADDALENA CANCER CENTER   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^d Vito Fazi Hospital   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^f Ospedale Civile   (Italy)

^g Italfarmaco SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOTEMUSTINE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; NAVELBINE; OXALIPLATIN; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; NITROSOUREA DERIVATIVE; ORGANOPHOSPHORUS COMPOUND;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL MENINGITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CATHETER INFECTION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENGRAFTMENT; ENTERITIS; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HODGKIN DISEASE; HUMAN; LARYNGITIS; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SALVAGE THERAPY; THROMBOCYTE COUNT; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT INFECTION; ADOLESCENT; AUTOTRANSPLANTATION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; KINETICS; LYMPHOMA; MIDDLE AGED; MORTALITY; PROCEDURES; SURVIVAL RATE; TOXICITY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; ETOPOSIDE; FEASIBILITY STUDIES; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KINETICS; LYMPHOMA; MALE; MELPHALAN; MIDDLE AGED; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955013982     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.318     Document Type: Article

References (42)

1. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588-595.
2. Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 2008; 87: 43-48.
3. Jantunen E, Kuittinen T, Nousiainen T. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma 2003; 44: 1151-1158.
4. Salar A, Sierra J, Gandarillas M, Caballero MD, Marín J, Lahuerta JJ et al. GEL/TAMO Spanish Cooperative Group. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant 2001; 27: 405-412.
5. Alessandrino EP, Bernasconi P, Colombo A, Caldera D, Martinelli G, Vitulo P et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000; 25: 309-313.
6. Kehrer JP. The effect of BCNU (carmustine) on tissue glutathione reductase activity. Toxicol Lett 1983; 17: 63-68.
7. Cao TM, Negrin RS, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Taylor TL et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000; 6: 387-394.
8. Hayes MT, Bartley J, Parsons PG, Eaglesham GK, Prakash AS. Mechanism of action of fotemustine, a new chloroethylnitrosourea anticancer agent: evidence for the formation of two DNA-reactive intermediates contributing to cytotoxicity. Biochemistry 1997; 36: 10646-10654.
9. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 1980; 23: 682-684.
10. Meulemans A, Giroux B, Hannoun P, Robine D, Henzel D. Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human, and rat brain biopsies. Chemotherapy 1991; 37: 86-92.
11. Meulemans A, Giroux B, Hannoun P, Henzel D, Bizzari JP, Mohler J. Permeability of two nitrosoureas, carmustine and fotemustine in rat cortex. Chemotherapy 1989; 35: 313-319.
12. Guaitani A, Corada M, Lucas C, Lemoine A, Garattini S, Bartosek I. Pharmacokinetics of fotemustine and BCNU in plasma, liver and tumor tissue of rats bearing two lines of Walker 256 carcinoma. Cancer Chemother Pharmacol 1991; 28: 293-297.
13. Boutin JA, Norbeck K, Moldeus P, Genton A, Paraire M, Bizzari JP et al. Effects of the new nitrosourea derivative, fotemustine, on the glutathione reductase activity in rat tissues in vivo and in isolated rat hepatocytes. Eur J Cancer Clin Oncol 1989; 25: 1311-1316.
14. Brandes AA, Tosoni A, Franceschi E, Blatt V, Santoro A, Faedi M et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol 2009; 64: 769-775 .
15. Fabrini MG, Silvano G, Lolli I, Perrone F, Marsella A, Scotti V et al. A multi-institutional phase II study on second-line fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 2009; 92: 79-86.
16. Scoccianti S, Detti B, Sardaro A, Iannalfi A, Meattini I, Leonulli BG et al. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs 2008; 19: 613-620.
17. Jacquillat C, Khayat D, Weil M, Bizzari JP. Clinical phase I-II study of the nitrosourea servier 10036 (fotemustine) in hematological malignancies. Proc ECCO 1987; 4: 314.
18. Rigal-Huguet F, Gaspard MH, Attal M, Giroux B, Lucas C, Pris J. Clinical pharmacokinetics of high doses of fotemustine with assessment of passage across the blood-brain barrier. Bull Cancer 1990; 77: 599.
19. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
20. Schmitz N, Buske C, Gisselbrecht C. Autologous stem cell transplantation in lymphoma. Semin Hematol 2007; 44: 234-245.
21. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008; 141: 3-13.
22. Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008; 19: 1312-1319.
23. Seshadri T, Kuruvilla J, Crump M, Keating A. Salvage therapy for relapsed/refractory diffuse large B cell lymphoma. Biol Blood Marrow Transplant 2008; 14: 259-267.
24. Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102: 1989-1996.
25. Fernandez HF, Escalón MP, Pereira D, Lazarus HM. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant 2007; 40: 505-513.
26. Gisselbrecht C. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br J Haematol 2008; 143: 607-621.
27. Zhang MM, Gopal AK. Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin Hematol 2008; 45: 118-125.
28. Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451-458.
29. van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 1995; 15: 549-555.
30. Seiden MV, Elias A, Ayash L, Hunt M, Eder JP, Schnipper LE et al. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimen. Bone Marrow Transplant 1992; 10: 57-63.
31. Phillips GL, Fay JW, Herzig GP, Herzig RH, Weiner RS, Wolff SN et al. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC 436650 and cryopreserved autologous marrow transplantation for refractory cancer: a phase I-II study. Cancer 1983; 52: 1792 - 1802.
32. De Rossi A, Rossi L, Laudisi A, Sini V, Toppo L, Marchesi F et al. Focus on fotemustine. J Exp Clin Cancer Res 2006; 25: 461-468.
33. Laquerriere A, Raguenez-Viotte G, Paraire M, Bizzari JP, Paresy M, Fillastre JP et al. Nitrosoureas lomustine, carmustine and fotemustine induced hepatotoxic perturbations in rats: biochemical. Morphological and flow cytometry studies. Eur J Cancer 1991; 27: 630-638.
34. Lee SM, Thatcher N, Dougal M, Margison GP. Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6- alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. Br J Cancer 1993; 67: 216-221.
35. Briegert M, Kaina B. Human monocytes, but not dendritic cells derived from them, are defective in base excision repair and hypersensitive to methylating agents. Cancer Res 2007; 67: 26-31.
36. Filippeschi S, Colombo T, Bassani D, De Francesco L, Arioli P, D'Incalci M et al. Antitumor activity of the novel nitrosourea S10036 in rodent tumors. Anticancer Res 1988; 8: 1351-1354.
37. Khayat D, Lokiec F, Bizzari JP, Weil M, Meeus L, Sellami M et al. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule. Cancer Res 1987; 47: 6782-6785.
38. Dumontet C, Jaubert J, Sebban C, Bouafia F, Ardiet C, Tranchand B et al. Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients. Ann Oncol 2003; 14: 615-622.
39. Mangiacavalli S, Pica G, Varettoni M, Lazzarino M, Corso A. Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients. Eur J Haematol 2009; 82: 240-241.
40. Escalón MP, Stefanovic A, Venkatraman A, Pereira D, Santos ES, Goodman M et al. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Bone Marrow Transplant 2009; 44: 89-96 .
41. Puig N, de la Rubia J, Remigia MJ, Jarque I, Martín G, Cupelli L et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 2006; 47: 1488-1494.
42. Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J et al. European Blood and Marrow Transplantation Mucositis Advisory Group. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM in patients receiving chemotherapy-European blood and marrow transplantation mucositis advisory group. J Clin Oncol 2008; 26: 1519-1525.